Key Developments: Allergan Inc (AGN)

AGN on New York Consolidated

165.65USD
10 Jul 2014
Price Change (% chg)

$0.46 (+0.28%)
Prev Close
$165.20
Open
$163.89
Day's High
$165.85
Day's Low
$163.06
Volume
1,592,621
Avg. Vol
4,442,024
52-wk High
$174.49
52-wk Low
$86.95

Search Stocks

Latest Key Developments (Source: Significant Developments)

Allergan Inc gives FY 2014 guidance in line with analysts' estimates; gives Q1 2014 guidance; EPS guidance below analysts' estimates - Conference Call
Wednesday, 5 Feb 2014 11:00am EST 

Allergan Inc:Expects FY 2014 product net sales in the range of $6.650 billion to $6.950 billion.Expects FY 2014 non-GAAP diluted earnings per share in the range of $5.36 to $5.48.Expects Q1 2014 product net sales in the range of $1.525 billion to $1.600 billion.Expects Q1 2014 non-GAAP diluted earnings per share in the range of $1.09 to $1.12.FY 2014 revenue of $6.801 billion and EPS of $5.45 - Thomson Reuters I/B/E/S.Q1 2014 revenue of $1.597 billion and EPS of $1.19 - Thomson Reuters I/B/E/S.  Full Article

Allergan Inc declares fourth quarter dividend
Wednesday, 5 Feb 2014 09:00am EST 

Allergan Inc:Declares a fourth quarter dividend of $0.05 per share.Payable on Mar. 21 to stockholders of record on Feb. 28.  Full Article

Allergan Inc completes sale of obesity intervention business
Monday, 2 Dec 2013 05:00pm EST 

Allergan Inc:Says it has completed the sale of its obesity intervention business to Apollo Endosurgery, Inc.Says it received a cash payment of $75 million and a $15 million minority equity interest in Apollo Endosurgery.  Full Article

Allergan Inc Raises Low End Of Prior FY 2013 Guidance; Issues Q4 2013 Guidance; EPS Guidance Below Analysts' Estimates
Tuesday, 29 Oct 2013 09:00am EDT 

Allergan Inc announced that for fiscal 2013, it expects total product net sales between $6.125 billion and $6.200 billion and Non-GAAP diluted earnings per share (EPS) attributable to stockholders from continuing operations between $4.74 and $4.76. For the fourth quarter of 2013, it expects total product net sales between $1.585 billion and $1.660 billion and Non-GAAP diluted earnings per share (EPS) attributable to stockholders from continuing operations between $1.31 and $1.33. According to I/B/E/S Estimates, analysts are expecting the Company to report EPS of $4.76 for fiscal 2013; revenue of $1.625 billion and EPS of $1.35 for the fourth quarter of 2013.  Full Article

Allergan Inc Declares Dividend
Tuesday, 29 Oct 2013 09:00am EDT 

Allergan Inc announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on December 11, 2013 to stockholders of record on November 20, 2013.  Full Article

Allergan Inc Receives FDA Approval For Juvederm Voluma XC
Wednesday, 23 Oct 2013 04:51pm EDT 

Allergan, Inc announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVEDERM VOLUMA XC, the first and only filler approved to temporarily correct age-related volume loss in the cheek area in adults over the age of 21. JUVEDERM VOLUMA XC helps create a more youthful appearance to the face and provides natural-looking and long-lasting results up to two years with optimal treatment.  Full Article

Medy Tox Inc Signs Technology Licensing Contract with Allergan, Inc.
Wednesday, 25 Sep 2013 06:05pm EDT 

Medy Tox Inc announced that it has signed a contract with Allergan, Inc., a Delaware-based corporation, and its subsidiaries, Allergan Pharmaceuticals Ireland, a company incorporated in Ireland, and Allergan Pharmaceuticals Holdings (Ireland), an unlimited company incorporated in Ireland (collectively referred to as “Allergan”), for the development and sale of neurotoxin candidate products. Allergan, Inc. was licensed with the exclusive development and distribution right in the United States, and other entities of Allergan will be the exclusive distributor of the Company's products in markets expect Korea. The contract amount is KRW 389,801,600,000 (USD 362,000,000).  Full Article

Allergan Inc Announces FDA Approval Of BOTOX Cosmetic (onabotulinumtoxinA) for Temporary Improvement Of Moderate To Severe Lateral Canthal Lines (Crow's Feet Lines) In Adults
Wednesday, 11 Sep 2013 09:07pm EDT 

Allergan Inc announced approval by the U.S. Food and Drug Administration (FDA) to market BOTOX Cosmetic (onabotulinumtoxinA), for an additional indication to temporarily treat moderate to severe lateral canthal lines, commonly known as 'crow's feet' lines. BOTOX Cosmetic is the first and only product of its kind approved for this indication. BOTOX Cosmetic, approved in the United States in 2002 for the temporary improvement of moderate to severe glabellar lines (frown lines between the brows) for patients aged 18 to 65 years, remains the number-one minimally invasive aesthetic medical treatment globally. The safety and efficacy of BOTOX Cosmetic as a treatment for crow's feet lines was demonstrated in two randomized, multi-center, placebo-controlled clinical trials. The studies enrolled more than 1,350 subjects with 833 subjects receiving treatment with BOTOX Cosmetic. The trial demonstrated that BOTOX Cosmetic was an effective treatment compared to the control group, which did not receive BOTOX Cosmetic treatment.  Full Article

Allergan Inc Raises Low End Of Prior FY 2013 Guidance To A Range In Line With Analysts' Estimates; Issues Q3 2013 Guidance In Line With Analysts' Estimates
Wednesday, 31 Jul 2013 09:00am EDT 

Allergan Inc announced that for fiscal 2013, it expects total product net sales between Total product net sales between $6.050 billion and $6.200 billion, Non-GAAP diluted earnings per share to be between $4.72 and $4.76. For the third quarter of 2013, it expects total product net sales between $1.500 billion and $1.575 billion. Non-GAAP diluted earnings per share attributable to stockholders from continuing operations between $1.18 and $1.20. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $6.16 billion and EPS of $4.74 for fiscal 2013; revenue of $1.517 billion and EPS of $1.20 for the third quarter of 2013.  Full Article

Elan Corporation PLC Seeks Bids From Allergan Inc and Forest Laboratories Inc-Reuters
Saturday, 13 Jul 2013 03:59pm EDT 

Reuters reported that Elan Corporation PLC is seeking first-round bids next week after drawing interest from a few drugmakers including Allergan Inc and Forest Laboratories Inc.  Full Article

Deals of the day- Mergers and acquisitions

(Adds Allergan, Fiat, Intesa Sanpaolo, Siemens, Omega Pharma, Mitsubishi, Sucafina, New Landsbanki, PSP Investment, African Bank Investments and Aareal)

Search Stocks